Methodological considerations in assessing GLP-1 receptor agonists and gastrointestinal cancer risk

Methodological considerations in assessing GLP-1 receptor agonists and gastrointestinal cancer risk

Saved in:

Bibliographic Details
Main Authors:	Cheng-Hsien Hung, Chun-Ting Lin, James Cheng-Chung Wei
Format:	Article
Language:	English
Published:	Elsevier 2024-12-01
Series:	Pharmacological Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1043661824004262
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist
by: Gentinetta S, et al.
Published: (2024-12-01)

Clarifying methodological approaches in the assessment of GLP-1 RAs and gastrointestinal cancer risk
by: Gisella Figlioli, et al.
Published: (2024-12-01)

Adverse effects of GLP – 1 Receptor Agonists
by: Anna Kasprzak, et al.
Published: (2025-02-01)

Gastrointestinal Safety Assessment of GLP-1 Receptor Agonists in the US: A Real-World Adverse Events Analysis from the FAERS Database
by: Samuel Prince Osei, et al.
Published: (2024-12-01)

GLP-1 Receptor Agonists’ Impact on Fertility - A Review
by: Joanna Wojda, et al.
Published: (2025-02-01)

Potential Use of GLP-1 and GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at?
by: Miodrag Janić, et al.
Published: (2024-12-01)

GLP-1 receptor agonist use does not increase risk of respiratory complications post-endoscopy
by: Jena Velji-Ibrahim, et al.
Published: (2025-01-01)

GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks
by: Ioannis Ilias, et al.
Published: (2025-01-01)

GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes
by: María Isabel del Olmo-Garcia, et al.
Published: (2018-01-01)

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Game Charger in the Field?
by: Georgia Doumani, et al.
Published: (2024-11-01)

Impact of GLP-1 Receptor Agonists on Psoriasis and Cardiovascular Comorbidities: A Narrative Review
by: Haran K, et al.
Published: (2024-11-01)

Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution
by: Stefan S. Du Plessis, et al.
Published: (2024-11-01)

Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different?
by: Chloé Amouyal, et al.
Published: (2016-01-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective
by: Dominique Xavier Brown, et al.
Published: (2012-01-01)

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
by: Patrycja Kupnicka, et al.
Published: (2024-11-01)

SGLT-2 Inhibitors’ and GLP-1 Receptor Agonists’ Influence on Neuronal and Glial Damage in Experimental Stroke
by: Anna Murasheva, et al.
Published: (2024-12-01)

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties
by: Chenqi Lu, et al.
Published: (2024-12-01)

GLP‐1 Receptor Agonists Alleviate Diabetic Kidney Injury via β‐Klotho‐Mediated Ferroptosis Inhibition
by: Shasha Tian, et al.
Published: (2025-01-01)

Holding GLP-1 Agonists Prior to Elective Procedures
by: Patient Safety Authority
Published: (2023-12-01)

Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists
by: Mayeesha Ahmed, et al.
Published: (2025-02-01)

Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen
by: Yi-Hsuan Lin, et al.
Published: (2022-12-01)

Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?
by: Paschalis Karakasis, et al.
Published: (2024-11-01)

Correction: Regimen comprising GLP‑1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre‑mixed insulin regimen
by: Yi‑Hsuan Lin, et al.
Published: (2024-11-01)

Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01)

Perioperative Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA) and Gastric Point Of Care Ultrasound (POCUS)
by: Sivasenthil Arumugam, et al.
Published: (2024-11-01)

Association between different GLP-1 receptor agonists and acute pancreatitis: case series and real-world pharmacovigilance analysis
by: Hui Guo, et al.
Published: (2024-11-01)

Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01)

Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time-control studyResearch in context
by: Julien Bezin, et al.
Published: (2025-02-01)

Syringaldehyde Alleviates Cardiac Hypertrophy Induced by Hyperglycemia in H9c2 Cells Through GLP-1 Receptor Signals
by: Yingxiao Li, et al.
Published: (2025-01-01)

Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials
by: Haoyang Guo, et al.
Published: (2025-03-01)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review
by: Serene Lee, et al.
Published: (2024-11-01)

Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials
by: Haijun Wan, et al.
Published: (2024-11-01)

The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk
by: M. Pilar Valdecantos, et al.
Published: (2024-11-01)

Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs
by: Rui Gao, et al.
Published: (2024-12-01)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes
by: Graciela Zambrano-Galván, et al.
Published: (2024-10-01)

Exploring the GLP-1–GLP-1R axis in porcine pancreas and gastrointestinal tract in vivo by ex vivo autoradiography
by: Jens Juul Holst, et al.
Published: (2021-03-01)

Knowledge, attitudes, and practices towards the use of GLP-1 receptor agonists for weight loss among the general population in Jordan; A cross-sectional study.
by: Rana Abutaima, et al.
Published: (2024-01-01)

Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives
by: Kosuke Sawami, et al.
Published: (2024-11-01)

The Impact of GLP-1 Agonist Therapy in Tibiotalar and Subtalar Fusion: A Propensity-Matched Analysis
by: Michael Levidy MD, et al.
Published: (2024-12-01)